Paper41404698
Biomarkers in the Management of Complement-Mediated Kidney Diseases in the Era of Complement Therapeutics.
Rizk DV and 5 others. Clin J Am Soc Nephrol, 2026. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Biomarkers in the Management of Complement-Mediated Kidney Diseases in the Era of Complement Therapeutics. Papers, record 41404698. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41404698
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Biomarkers in the Management of Complement-Mediated Kidney Diseases in the Era of Complement Therapeutics.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Complement System Proteins | Major topic |
| Kidney Diseases | Major topic |
| Complement Activation | Major topic |
| Complement Inactivating Agents | Major topic |
| Humans | |
| Biomarkers | |
| Predictive Value of Tests |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | PubMed |
Source PubMed
References128
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38145741 | Compassionate Use Narsoplimab for Severe Refractory Transplantation-Associated Thrombotic Microangiopathy in Children. | Transplant Cell Ther | 2024 | https://conductscience.org/library/papers/38145741 | PubMed |
| 2 | 40177195 | Research progress on the roles of complement in liver injury. | World J Hepatol | 2025 | https://conductscience.org/library/papers/40177195 | PubMed |
| 3 | 24578331 | Association of C4d deposition with clinical outcomes in IgA nephropathy. | Clin J Am Soc Nephrol | 2014 | https://conductscience.org/library/papers/24578331 | PubMed |
| 4 | 31477814 | Utility of immunohistochemistry with C3d in C3 glomerulopathy. | Mod Pathol | 2020 | https://conductscience.org/library/papers/31477814 | PubMed |
| 5 | 39455063 | Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial. | J Am Soc Nephrol | 2025 | https://conductscience.org/library/papers/39455063 | PubMed |
| 6 | 37914086 | Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. | Kidney Int | 2024 | https://conductscience.org/library/papers/37914086 | PubMed |
| 7 | 34379175 | Complement activation in IgA nephropathy. | Semin Immunopathol | 2021 | https://conductscience.org/library/papers/34379175 | PubMed |
| 8 | 25877499 | Levels in plasma of the serine proteases and associated proteins of the lectin pathway are altered in patients with systemic lupus erythematosus. | J Rheumatol | 2015 | https://conductscience.org/library/papers/25877499 | PubMed |
| 9 | 33962553 | Complement testing in the clinical laboratory. | Crit Rev Clin Lab Sci | 2021 | https://conductscience.org/library/papers/33962553 | PubMed |
| 10 | 36404708 | Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan. | Am J Nephrol | 2022 | https://conductscience.org/library/papers/36404708 | PubMed |
| 11 | 30655025 | Glomerular membrane attack complex is not a reliable marker of ongoing C5 activation in lupus nephritis. | Kidney Int | 2019 | https://conductscience.org/library/papers/30655025 | PubMed |
| 12 | 25780008 | Effect of blood sampling, processing, and storage on the measurement of complement activation biomarkers. | Am J Clin Pathol | 2015 | https://conductscience.org/library/papers/25780008 | PubMed |
| 13 | 33841408 | Glomerular Immune Deposition in MPO-ANCA Associated Glomerulonephritis Is Associated With Poor Renal Survival. | Front Immunol | 2021 | https://conductscience.org/library/papers/33841408 | PubMed |
| 14 | 39803605 | Evaluating Avacopan in the Treatment of ANCA-Associated Vasculitis: Design, Development and Positioning of Therapy. | Drug Des Devel Ther | 2025 | https://conductscience.org/library/papers/39803605 | PubMed |
| 15 | 33536243 | Inherited Kidney Complement Diseases. | Clin J Am Soc Nephrol | 2021 | https://conductscience.org/library/papers/33536243 | PubMed |
| 16 | 29361307 | Renal tubule injury: a driving force toward chronic kidney disease. | Kidney Int | 2018 | https://conductscience.org/library/papers/29361307 | PubMed |
| 17 | 37069992 | Proteomic Analysis of Complement Proteins in Glomerular Diseases. | Kidney Int Rep | 2023 | https://conductscience.org/library/papers/37069992 | PubMed |
| 18 | 33568389 | Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme. | Lupus Sci Med | 2021 | https://conductscience.org/library/papers/33568389 | PubMed |
| 19 | 36161656 | With complements: C3 inhibition in the clinic. | Immunol Rev | 2023 | https://conductscience.org/library/papers/36161656 | PubMed |
| 20 | 7678717 | Glomerular C3c localization indicates ongoing immune deposit formation and complement activation in experimental glomerulonephritis. | Am J Pathol | 1993 | https://conductscience.org/library/papers/7678717 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42530828 | The Alternative Complement Pathway in IgA Nephropathy: A Podcast for Advanced Practice Providers. | Adv Ther | 2026 | https://conductscience.org/library/papers/42530828 | PubMed |
| 42387937 | Complement Inhibition in the Clinic: Are We Doing Enough to Protect Patients From Infection? | Eur J Immunol | 2026 | https://conductscience.org/library/papers/42387937 | PubMed |
| 42303232 | Eculizumab for rapidly progressive glomerulonephritis in children. | Nephrol Dial Transplant | 2026 | https://conductscience.org/library/papers/42303232 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41404698
GET https://conductscience.org/api/papers/v1/41404698/references?page=2